Molecules, Vol. 28, Pages 6142: Glycyrrhiza glabra L. Extracts and Other Therapeutics against SARS-CoV-2 in Central Eurasia: Available but Overlooked

Conclusions: The synthetic, low-molecular-weight compound Cridanimod suppresses SARS-CoV-2 replication at notably low concentrations, and this drug is not toxic to cells at therapeutic concentrations. In contrast to its role as an inducer of interferons, Cridanimod is active in cells that have a genetic defect in interferon production, suggesting a different mechanism of action. Cridanimod is an attractive drug for inclusion in clinical trials against SARS-CoV-2 and, presumably, other coronaviruses. The extract from licorice shows low activity against SARS-CoV-2. At the same time, high doses of 2 g/kg of this plant extract show little or no acute toxicity in animal studies; for this reason, licorice products can still be considered for further development as a safe, orally administered adjunctive therapy.

Source: Molecules - August 19, 2023 Category: Chemistry Authors: Murat Zh. Zhurinov Alfira F. Miftakhova Viktoriya Keyer Zarina T. Shulgau Elena V. Solodova Maxat K. Kalykberdiyev Arlan Z. Abilmagzhanov Eldar T. Talgatov Sauyk Ait Alexandr V. Shustov Tags: Article Source Type: research